| 國立成功大學 |
2023 |
EZH2-mediated epigenetic silencing of tumor-suppressive let-7c/miR-99a cluster by hepatitis B virus X antigen enhances hepatocellular carcinoma progression and metastasis
|
Wu, C.-S.;Chien, Y.-C.;‐J, Yen C.;Wu, J.-Y.;Bai, L.-Y.;Yu, Yu Y.-L. |
| 國立成功大學 |
2023 |
The impact of preoperative waiting time in Stage II–III gastric or gastroesophageal junction cancer: A population-based cohort study
|
Yen, C.-C.;Yang, Yang Y.-H.;Ku, H.-Y.;Hu, Hu H.-M.;Lo, S.-S.;Chang, H.-C.;Chao, Y.;Chen, J.-S.;Wang, H.-P.;Wang, T.-E.;Bai, L.-Y.;Wu, M.-S.;Yen, C.-J.;Chen, L.-T.;Shan, Y.-S. |
| 臺大學術典藏 |
2022-08-23T02:35:00Z |
Case Report: Maintenance Nivolumab in Complete Responder After Multimodality Therapy in Metastatic Pancreatic Adenocarcinoma
|
Bai L.-Y.; Hsu C.; Yang S.-H.; Lee J.-C.; Chen B.-B.; SUNG-HSIN KUO |
| 臺大學術典藏 |
2022-08-19T00:20:24Z |
Case Report: Maintenance Nivolumab in Complete Responder After Multimodality Therapy in Metastatic Pancreatic Adenocarcinoma
|
Yang S.-H.; Kuo S.-H.; Bai L.-Y.; Lee J.-C.; Chen B.-B.; CHIUN HSU |
| 臺大學術典藏 |
2022-04-20T08:12:03Z |
Survival outcomes of management in metastatic gastric adenocarcinoma patients
|
Hu H.-M.; Tsai H.-J.; Ku H.-Y.; Lo S.-S.; Shan Y.-S.; Chang H.-C.; Chao Y.; Chen J.-S.; Chen S.-C.; CHUN-JU CHIANG; Li A.F.-Y.; Wang H.-P.; Wang T.-E.; Bai L.-Y.; Wu M.-S.; Chen L.-T.; Liu T.-W.; Yang Y.-H. |
| 臺大學術典藏 |
2022-03-31T02:39:17Z |
Young nasopharyngeal cancer patients with radiotherapy and chemotherapy are most prone to ischaemic risk of stroke: A national database, controlled cohort study
|
Chu C.-N.; PAU-CHUNG CHEN; Bai L.-Y.; Muo C.-H.; Sung F.-C.; Chen S.-W. |
| 臺大學術典藏 |
2022-03-10T02:31:40Z |
Multimodel assessment of BRCA1 mutations in Taiwanese (ethnic Chinese) women with early-onset, bilateral or familial breast cancer
|
Kuo W.-H.; PO-HAN LIN; Huang A.-C.; Chien Y.-H.; Liu T.-P.; Lu Y.-S.; Bai L.-Y.; Sargeant A.M.; Lin C.-H.; Cheng A.-L.; Hsieh F.-J.; Hwu W.-L.; Chang K.-J. |
| 臺大學術典藏 |
2022-03-10T02:31:40Z |
Prognostic impact of allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia patients with internal tandem duplication of FLT3
|
PO-HAN LIN; Lin C.-C.; Yang H.-I.; Li L.-Y.; Bai L.-Y.; Chiu C.-F.; Liao Y.-M.; Lin C.-Y.; Hsieh C.-Y.; Lin C.-Y.; Ho C.-M.; Yang S.-F.; Peng C.-T.; Tsai F.-J.; Yeh S.-P. |
| 臺大學術典藏 |
2022-03-10T02:31:39Z |
OSU-A9, an indole-3-carbinol derivative, induces cytotoxicity in acute myeloid leukemia through reactive oxygen species-mediated apoptosis
|
Bai L.-Y.; Weng J.-R.; Chiu C.-F.; Wu C.-Y.; Yeh S.-P.; Sargeant A.M.; PO-HAN LIN; Liao Y.-M. |
| 臺大學術典藏 |
2022-03-10T02:31:38Z |
Palonosetron and dexamethasone for the prevention of nausea and vomiting in patients receiving allogeneic hematopoietic stem cell transplantation
|
Yeh S.-P.; Lo W.-C.; Hsieh C.-Y.; Bai L.-Y.; Lin C.-C.; PO-HAN LIN; Lin C.-Y.; Liao Y.-M.; Chiu C.-F. |
| 臺大學術典藏 |
2022-03-10T02:31:38Z |
Safety and efficacy of pegylated liposomal doxorubicinbased adjuvant chemotherapy in patients with stage I-III triple-negative breast cancer
|
Lien M.-Y.; Liu L.-C.; Wang H.-C.; Yeh M.-H.; Chen C.-J.; Yeh S.-P.; Bai L.-Y.; Liao Y.-M.; Lin C.-Y.; Hsieh C.-Y.; Lin C.-C.; Li L.-Y.; PO-HAN LIN; Chiu C.-F. |
| 臺大學術典藏 |
2022-03-10T02:31:36Z |
A targeted next-generation sequencing in the molecular risk stratification of adult acute myeloid leukemia: implications for clinical practice
|
PO-HAN LIN; Li H.-Y.; Fan S.-C.; Yuan T.-H.; Chen M.; Hsu Y.-H.; Yang Y.-H.; Li L.-Y.; Yeh S.-P.; Bai L.-Y.; Liao Y.-M.; Lin C.-Y.; Hsieh C.-Y.; Lin C.-C.; Lin C.-H.; Lien M.-Y.; Chen T.-T.; Ni Y.-H.; Chiu C.-F. |
| 臺大學術典藏 |
2022-03-08T03:44:01Z |
Liposomal irinotecan pre-emptive dose reduction in patients with pancreatic ductal adenocarcinoma: 667 patients�� experience within a population-based study
|
Chiu T.-J.; Su Y.-Y.; SHIH-HUNG YANG; Li C.-P.; Bai L.-Y.; Chiang N.-J.; Chuang S.-C.; Shan Y.-S.; Chan D.-C.; Chen L.-T.; Yen C.-J.; Peng C.-M.; Chen Y.-Y.; Chen J.-S.; Chou W.-C. |
| 臺大學術典藏 |
2022-03-08T03:44:01Z |
Negative prognostic implications of splenomegaly in nivolumab-treated advanced or recurrent pancreatic adenocarcinoma
|
SHIH-HUNG YANG; Lu L.-C.; Kao H.-F.; Chen B.-B.; Kuo T.-C.; Kuo S.-H.; Tien Y.-W.; Bai L.-Y.; Cheng A.-L.; Yeh K.-H. |
| 臺大學術典藏 |
2022-02-21T02:04:35Z |
Exploring Markers of Exhausted CD8 T Cells to Predict Response to Immune Checkpoint Inhibitor Therapy for Hepatocellular Carcinoma
|
Hsu C.-L.; Ou D.-L.; Bai L.-Y.; Chen C.-W.; Lin L.; Huang S.-F.; ANN-LII CHENG; Jeng Y.-M.; Hsu C. |
| 臺大學術典藏 |
2022-02-14T07:10:49Z |
Exploring Markers of Exhausted CD8 T Cells to Predict Response to Immune Checkpoint Inhibitor Therapy for Hepatocellular Carcinoma
|
Hsu C.-L.; Ou D.-L.; Bai L.-Y.; Chen C.-W.; Lin L.; Huang S.-F.; Cheng A.-L.; YUNG-MING JENG; Hsu C. |
| 臺大學術典藏 |
2022-02-14T05:27:14Z |
Survival outcomes of management in metastatic gastric adenocarcinoma patients
|
Hu H.-M.; Tsai H.-J.; Ku H.-Y.; Lo S.-S.; Shan Y.-S.; Chang H.-C.; Chao Y.; Chen J.-S.; Chen S.-C.; Chiang C.-J.; Li A.F.-Y.; HSIU-PO WANG; Wang T.-E.; Bai L.-Y.; Wu M.-S.; Chen L.-T.; Liu T.-W.; Yang Y.-H. |
| 臺大學術典藏 |
2022-02-08T06:27:19Z |
Exploring Markers of Exhausted CD8 T Cells to Predict Response to Immune Checkpoint Inhibitor Therapy for Hepatocellular Carcinoma
|
Hsu C.-L.; DA-LIANG OU; Bai L.-Y.; Chen C.-W.; Lin L.; Huang S.-F.; Cheng A.-L.; Jeng Y.-M.; Hsu C. |
| 臺大學術典藏 |
2022-02-07T07:49:00Z |
Negative prognostic implications of splenomegaly in nivolumab-treated advanced or recurrent pancreatic adenocarcinoma
|
Yang S.-H.; Lu L.-C.; Kao H.-F.; Chen B.-B.; Kuo T.-C.; SUNG-HSIN KUO; Tien Y.-W.; Bai L.-Y.; Cheng A.-L.; Yeh K.-H. |
| 臺大學術典藏 |
2022-01-25T07:24:16Z |
Survival outcomes of management in metastatic gastric adenocarcinoma patients
|
Hu H.-M.; Tsai H.-J.; Ku H.-Y.; Lo S.-S.; Shan Y.-S.; Chang H.-C.; Chao Y.; Chen J.-S.; Chen S.-C.; Chiang C.-J.; Li A.F.-Y.; Wang H.-P.; Wang T.-E.; Bai L.-Y.; MING-SHIANG WU; Chen L.-T.; Liu T.-W.; Yang Y.-H. |
| 臺大學術典藏 |
2022-01-05T03:36:40Z |
Exploration of predictors of benefit from nivolumab monotherapy for patients with pretreated advanced gastric and gastroesophageal junction cancer: post hoc subanalysis from the ATTRACTION-2 study
|
Kang Y.-K.; Morita S.; Satoh T.; Ryu M.-H.; Chao Y.; Kato K.; Chung H.C.; Chen J.-S.; Muro K.; Kang W.K.; KUN-HUEI YEH; Yoshikawa T.; Oh S.C.; Bai L.-Y.; Tamura T.; Lee K.-W.; Hamamoto Y.; Kim J.G.; Chin K.; Oh D.-Y.; Minashi K.; Cho J.Y.; Tsuda M.; Sameshima H.; Chen L.-T.; Boku N. |
| 臺大學術典藏 |
2022-01-05T03:36:40Z |
Negative prognostic implications of splenomegaly in nivolumab-treated advanced or recurrent pancreatic adenocarcinoma
|
Yang S.-H.; Lu L.-C.; Kao H.-F.; Chen B.-B.; Kuo T.-C.; Kuo S.-H.; Tien Y.-W.; Bai L.-Y.; Cheng A.-L.; KUN-HUEI YEH |
| 臺大學術典藏 |
2022-01-05T03:36:39Z |
Nivolumab in previously treated advanced gastric cancer (ATTRACTION-2): 3-year update and outcome of treatment beyond progression with nivolumab
|
Boku N.; Satoh T.; Ryu M.-H.; Chao Y.; Kato K.; Chung H.C.; Chen J.-S.; Muro K.; Kang W.K.; KUN-HUEI YEH; Yoshikawa T.; Oh S.C.; Bai L.-Y.; Tamura T.; Lee K.-W.; Hamamoto Y.; Kim J.G.; Chin K.; Oh D.-Y.; Minashi K.; Cho J.Y.; Tsuda M.; Nishiyama T.; Chen L.-T.; Kang Y.-K. |
| 國立成功大學 |
2022 |
Impaired Chromatin Remodeling Predicts Better Survival to Modified Gemcitabine and S-1 plus Nivolumab in Advanced Biliary Tract Cancer: A Phase II T1219 Study
|
Chiang, N.-J.;Tan, K.T.;Bai, L.-Y.;Hsiao, C.-F.;Huang, C.-Y.;Hung, Y.-P.;Huang, C.-J.;Chen, S.-C.;Shan, Y.-S.;Chao, Y.;Huang, Y.-H.;Lee, I.-C.;Lee, P.-C.;Su, Y.-Y.;Chen, S.-J.;Yeh, C.-N.;Chen, L.-T.;Chen, M.-H. |
| 國立成功大學 |
2022 |
Effect of previous conventional irinotecan treatment in patients with pancreatic cancer being treated with liposomal irinotecan plus 5-fluorouracil and leucovorin
|
Chiu, T.-J.;Yang, S.-H.;Chiu, S.-C.;Hsueh, S.-W.;Chiang, N.-J.;Li, C.-P.;Bai, L.-Y.;Cheng, F.-M.;Chuang, S.-C.;Shan, Y.-S.;Chan, D.-C.;Chen, L.-T.;Yen, C.-J.;Peng, C.-M.;Su, Y.-Y.;Chen, Y.-Y.;Chen, J.-S.;Chou, W.-C. |
